From now until 11:59 p.m. tonight, I’m giving away one free year of access to my profit-gushing Lightning Trend Trader service.
Normally we charge $4,000 for a single year.
But today I’ve decided to waive that fee for one full year of service.
And I believe that if you take me up on my offer...
By this time next year, you could become a millionaire.
My research has helped subscribers accomplish this before...
Vietnam veteran Anthony Valentino said he and his brother made approximately $1.3 million following my advice last year.
Kevin Hannigan wrote to tell me that after using my research as his go-to advice, his “investment account totaled in excess of $2.7 million.”
So why would I give away a free year of research that’s performing so well?
Let me tell you a quick story.
Last February, I uncovered a surging biotech, AbbVie, with a revolutionary Alzheimer’s breakthrough.
So I created an urgent video presentation, much like the one you are watching right now, detailing the investment opportunity...
In it, I made clear just how much money I expected people could make in one year.
Here are my exact words...
That’s right. I was so confident, I guaranteed it.
Yet not everyone believed me.
One online commenter said that my prediction “smells like pig feces.”
Another sarcastically mocked my guarantee, as if there were no way I could deliver.
But they couldn’t see what I saw. They didn’t know about the Alzheimer’s breakthrough that was coming.
And sure enough...
I delivered a return 4 1/2 larger than my 519% guarantee...
A return of 2,381%, to be exact – my personal record, and the second-highest ever in the history of The Oxford Club.
Anthony Valentino, whom I just mentioned, was one of the few people who took me up on the offer.
And it changed his life forever.
Ten months later, he wrote in and said...
It was a HUGE win for a small group of our subscribers... one of the biggest EVER in our 25-plus year history.
And yet... there was one problem.
You missed it.
In fact, only 350 people claimed a copy of the report where I showed exactly how to profit from this opportunity.
Given that there are 150,000 Oxford Club subscribers, that’s unacceptable.
Less than 1% of our Members took action and captured this life-changing gain.
That’s why, today, we’re making damn sure it doesn’t happen again.
In a private, closed-door meeting, our CEO, Julia Guth, authorized me to do something unprecedented...
We’re giving away a free year of my research service to whomever responds to claim it today.
That way, you have a full 12 months to follow my new millionaire-making play with me at your side.
We could end up giving away $2 million worth of subscriptions – or more.
But it’s worth it.
Our whole mission here at The Oxford Club is to help you achieve complete financial freedom.
Just think about the life you’d live as a millionaire.
Anthony Valentino took eight family members to Sicily for Christmas and New Year's...
And he plans to take his family on three international vacations every year before his granddaughters reach college age.
Just like him, you could go on vacations without worrying about a tight budget...
Or give back to your church or a charity, or start a scholarship program.
All you have to do is watch this video to the end and follow my instructions to claim your FREE year.
And while we normally cap new subscriptions to my Lightning Trend Trader service...
This time, there is NO LIMIT to the number of people I’m letting in.
Because I have a recommendation ready that could beat my 2,381% gain...
One that would break all records here at The Oxford Club...
And I don’t want ANYONE to miss it.
Given my PROVEN strategy, you’re looking at capturing a 3,000% monster of a trade.
And once again, I’m willing to guarantee it.
My Subscribers Are Getting Rich...
and This Is Your Chance to Join Them!
My name, by the way, is Marc Lichtenfeld.
I’m the Chief Income Strategist here at The Oxford Club.
My life’s mission is to help you grow and preserve your wealth swiftly and safely.
And I love it. It’s my dream job.
Between Wall Street bleeding you dry with fees...
And the mainstream financial media feeding you misinformation...
But I’m here to change that.
I’ve been in this business a long time, and I’ve made a big difference in people’s lives.
Here’s the proof.
I’ve delivered 133 triple- and quadruple-digit gains on my best recommendations in my time here at The Oxford Club...
My Lightning Trend Trader service has outperformed the S&P 500’s average annual return by an incredible 2,052%.
Here’s what that has looked like since 2012.
And these aren’t just numbers on a page.
I have countless letters in my inbox from real subscribers who are living their dreams because of my research.
Gil Partridge wrote in and said...
Henry Bollinger said...
Paul Yates says...
Stephen Ellifsohn said...
Colin Jones said...
Malcom Severson sent me one of my favorite notes I’ve ever gotten from a reader. It’s a little long, but I think it’s important to share.
For me, this is what my job is all about.
It’s about helping people to take control of their lives... to take pride in providing for themselves and others.
That’s why I’m making absolutely sure you don’t miss the biggest trade recommendation of my career...
One with a 3,000% potential that could make you a millionaire in 12 months.
Of course, 3,000% is exceptional – results like that don’t happen every day. But that’s exactly why I want to give you a FREE year of Lightning Trend Trader today... so you don’t miss this rare opportunity.
Even a fraction of that gain would be life-changing...
And there’s a good reason I’m so confident.
Get Fabulously Wealthy With These “Lightning Strike” Market Events
I’ve been able to identify some of the biggest winners in the history of the market.
The strategy I use is a powerful, proven way to make a LOT of money in a short period of time.
It harnesses the power of special catalysts...
That send seemingly normal stocks to the moon.
I call them “Lightning Strikes.”
A stock might go nowhere for YEARS...
But then, when a Lightning Strike occurs, you have the opportunity to become a millionaire.
That’s why I’ve dedicated so much of my life to becoming the foremost expert on these potent market events.
My track record is loaded with examples of subscribers getting the opportunity to make huge money on Lightning Strikes.
Let me show you...
A couple of years ago, I discovered a company called Onyx Pharmaceuticals. It was successfully treating kidney and liver cancers with a drug called Nexavar.
The broader market didn’t fully appreciate what a home run this was...
But I knew it wouldn’t stay cheap for long.
So on April 2, I recommended that my subscribers take a position in Onyx.
Sure enough, lightning struck.
And subscribers had the chance to lock in a 330% gain in just a couple of months.
$5,000 turned into $21,500.
Similarly, my subscribers had the chance at a massive payday with Celldex Therapeutics.
For about a year, the stock did absolutely nothing.
But I knew a Lightning Strike was coming up.
Celldex was targeting triple-negative breast cancer – a rare, deadlier form of the disease. And it was getting ready to release Phase 2 clinical trial data – a powerful type of Lightning Strike.
So I sent an email to my subscribers on November 28... right before this big event.
And shares in Celldex SURGED 419% in under a year!
The stock soared from $6 to more than $30!
And $5,000 turned into nearly $26,000 with ease.
Around the same time, I discovered NPS Pharmaceuticals.
It sold a drug called Gattex to treat short bowel syndrome. It’s a rare disease affecting as few as 12,000 Americans.
So it’s really no wonder why Wall Street wasn’t paying close attention.
NPS was doing practically nothing for an entire year.
But I knew how revolutionary its drug Gattex was.
Sufferers of short bowel syndrome experience severe malnutrition.
Patients must be hooked up to a feeding tube for hours a day.
But Gattex was set to transform these patients’ lives. I knew it was going to be a big Lightning Strike for NPS.
So I sent an email to my Lightning Trend Trader subscribers.
Just a few months later...
Those who followed my recommendation saw a 775% gain in their accounts!
Every $5,000 exploded into $43,750.
That’s a lot of money in such a short period of time.
And then, of course there was the giant win in AbbVie.
It was hovering around the same price for three years. It seemed like the stock was dead in the water.
But then I discovered that it had partnered with Google on an incredible Alzheimer’s breakthrough.
I quickly shot a special video on the opportunity and sent it to all my subscribers.
Then, just as I predicted, lightning struck. The stock went on a tear.
My subscribers had the chance to lock in a 2,381% gain in just 10 months.
Anthony Valentino and his brother made $1.3 million on this very recommendation.
That’s the power of Lightning Strikes.
Of course, this is just a small sampling of the best wins I’ve helped my subscribers collect.
In my time at The Oxford Club, I’ve recommended 133 triple- and quadruple-digit gains across my services.
It’s proof that you CAN beat the market...
And you CAN catch up on your retirement...
If you know where to look.
The problem is, most financial advisers will tell you the only way to make money is to sit on an index fund for 40 years and pray for 7% annually.
That bad advice is so deeply ingrained into most investors’ brains.
And that’s probably why the vast majority of Oxford Club subscribers missed out on the chance to make a million dollars on my huge AbbVie win.
And today, you’re getting a second chance.
I’ve found a new stock about to experience a Lightning Strike. And I believe this one could set my all-time record for gains.
It’s bigger and better than AbbVie.
And I believe it could hand you a 30X gain.
The reason I’m so confident is simple.
A 3,000% winner is possible when you see the telltale signs of a Lightning Strike about to hit.
Gains that big are relatively common in the biotech market.
Take a look at Genzyme, which experienced a Lightning Strike not too long after its IPO. It started releasing great clinical trial data for a drug to help treat Gaucher’s disease...
And this company went on to deliver 3,168%!
BioMarin Pharmaceutical was trading for less than $4 on November 5 a few years ago. Then, lightning struck. It announced Phase 3 trials for its drug Phenoptin.
The stock went on to deliver 3,637% gains!
MiMedx Group experienced the same. It delivered 3,740%!
Again, exceptional examples like these are certainly rare. But like I said, just one of these Lightning Strikes can light a stock up and multiply your money many times over.
And the play I want to share with you today is definitely primed for a Lightning Strike.
This company has an incredibly profitable business model...
One that allows it to capture millions in profits from drug sales... WITHOUT paying for the expensive FDA testing.
And it has deals with pharma giants like Merck, Pfizer, Eli Lilly, Novartis and more...
But here’s what makes it truly unique.
I believe it’s about to experience not just one Lightning Strike...
But a bevy of Lightning Strikes one after another.
This company is basically a lightning rod.
It has so many catalysts coming up, it would take a nearly impossible series of events to keep this stock price down.
Of course, there are still risks. Anyone who tells you they can predict the market with 100% accuracy is full of it. There’s always the chance you’ll lose some money or make less than projected.
But the fact of the matter is... Lightning Strikes are the most powerful catalysts in the market...
And the next one for this company is coming on June 30.
You’ll want to be in well before that happens.
In fact, I recommend getting in TODAY for maximum profit potential. Because once the momentum gets going, the price will shoot to the stars.
I’m going to give you all the details on this special stock in the next few minutes...
I want you to have it as part of your FREE year of Lightning Trend Trader...
And while there’s no limit to the number of people who can claim their free year of my market-trouncing service, Lightning Trend Trader...
This IS a limited-time offer.
After all, I can’t give away $4,000 subscriptions forever.
After tonight at midnight, you may never see this invitation again.
So while there’s still time...
Here’s what you need to know about the potential 3,000% winner... and its upcoming parade of Lightning Strikes.
Ride This Revolutionary Business Model
to Your Next Million
The 3,000% winner is unlike any other company you’ve ever heard of...
And it’s the best-kept secret in the market.
Let me explain.
You’re probably familiar with the concept of royalties.
What most people know about royalties is that they’re a payment you receive over and over again, usually on a song or a book.
But what most people DON’T know is...
There are ALL sorts of ways to collect royalties.
And the companies that collect these royalties can make a fortune.
Take MV Oil Trust, for example.
It holds royalty interests in about 1,000 oil and natural gas fields.
It doesn't do ANY work.
It just gets a piece of the profits.
Over the years, it’s collected $266 million in royalties.
And as a result, MV Oil Trust delivered a 563% gain!
Wheaton Precious Metals is another great example.
It collects silver and gold royalties.
And as a result, investors in its business earned as much as 1,711%!
$5,000 would have turned into $90,550 in just a few years.
And then there’s Qualcomm.
It currently collects patent royalties of $16.25 on smartphones.
And its stock has increased as much as 7,181% over time!
Companies that collect royalties are some of the most profitable types of businesses you can invest in. Period.
Frank Holmes, CEO of U.S. Global Investors, writes that...
And the company I’m talking about today is in an even better sector for royalties.
Instead of collecting on oil... gold... or tech patents...
This company collects royalties on pharmaceutical drugs – which may just be the most lucrative business in the world today.
BETTER Royalties... BIGGER Profits
You see, drug royalties offer gigantic payouts.
And the companies that own the rights to these royalties can make a fortune.
They’re able to collect this cash simply by investing in a drug before it goes to market. Then the cash rolls in for years and years.
And they don’t have to spend millions on research and development, FDA testing or marketing.
If you can identify a winning drug, this is EASY MONEY.
Because you’re legally entitled to receive the royalty for years... sometimes forever!
Just imagine the following scenario with me real quick.
Let’s say you were able to secure a royalty on the blockbuster of all blockbuster drugs, Lipitor. And let’s say the rate was something tiny – like half a percent.
That would mean that for every $100 of Lipitor sold, you’d make $0.50. It’s a small cut.
But you don’t have to do anything. You own the rights in perpetuity. You just collect every single time somebody walks into a pharmacy and picks up their prescription.
At its peak, Lipitor did $12.9 BILLION in sales. Even with your small cut, that means you would have made as much as $64.5 million in a year.
And with Lipitor’s lifetime sales clocking in at $141 billion, that means over time you would have collected a whopping $705 million.
Just by securing a small 0.5% royalty stream.
And here’s the thing... royalty agreements are usually much higher than that. The company I’m talking about today collects royalties as high as 20%!
All that money... and you didn’t have to lift a finger. No research costs... no marketing costs... no logistics costs...
Now, imagine how great life would be if you truly had access to the benefits of a drug royalty like that.
You may think it’s impossible, but with the company I’m about to show you, that’s exactly what you’ll get.
It’s a chance to reap the benefits every single time somebody picks up a prescription anywhere in the country.
In fact, the company I’m looking at is primed to be the No. 1 drug royalty company in the world.
A Nearly Endless List of Upcoming Lightning Strikes!
This company isn’t just primed for one Lightning Strike...
But a whole storm of them.
It has one of the biggest portfolios of drug royalty streams out there, which means every time one of these drugs has a big sales quarter... another Lightning Strike will send this royalty company higher and higher.
Over the last few years, it’s quietly gone around making deals with virtually all of Big Pharma.
It has agreements with...
It has income streams established on not one or two but 18 FDA-approved drugs...
These include drugs that treat major diseases like cancer... osteoporosis... bipolar disorder... epilepsy... and more.
These 18 drug royalties alone are set to hand the company a projected $116 million in revenue this year... without it having to develop or market any drugs itself.
But here’s the thing.
This company has also ALREADY locked down royalties on drugs in the approval process.
In total, it has 165 drug programs it’s set to collect on.
So once these drugs hit the market...
Revenue could breach $5.8 BILLION.
Let me show you exactly how this works with each drug.
A Proprietary Way of Collecting Royalties for Huge, Protected Profits
This company’s main offering is a proprietary molecule it acquired from scientists at the University of Kansas... and now licenses out to other businesses.
This molecule is really special. It makes drugs better, more stable and better absorbed by your body.
In fact, it can make drugs up to 25,000 times better absorbed.
Of course, drug companies want their products to be as effective as possible.
This technology – and others like it – is why this no-name biotech has been able to make deals with pharmaceutical giants like Pfizer, Merck, Novartis, Gilead, Eli Lilly and more.
Drug companies add this molecule to make sure their drugs are as effective as possible.
Then, when the FDA approves it, this molecule becomes a permanent part of a drug’s formula.
That means every time the drug is sold, our company collects a piece of the action.
Here’s an example.
Millions in Revenue... WITHOUT Lifting a Finger!
Amgen has a drug called Kyprolis.
Kyprolis targets multiple myeloma, a cancer of the white blood cells.
It goes after a specific enzyme to make tumor cells self-destruct.
But to make the drug even better, Amgen added this royalty company’s proprietary molecule to the mix.
In clinical trials, this combination kept patients from getting worse – and helped them live 20% longer.
For a disease with a 50% survival rate (in other words, a coin toss), this drug was a godsend.
Amgen pulled in $835 million from Kyprolis last year.
But because it used this royalty company’s proprietary molecule, Amgen had to pay our drug royalty company $17.6 million.
Now, let me be clear. The royalty company didn’t have to develop Kyprolis... or market it... or do a lick of work distributing it.
Amgen did all that work.
And because of this relationship, every time Amgen reports earnings, it’s a potential Lightning Strike for our small royalty company.
Pretty impressive, right?
But remember, Kyprolis is just one of the many drugs in our royalty company’s portfolio.
This molecule is actually in 10 FDA-approved drugs. And the royalty company currently collects on all of them.
But that’s just the beginning.
There are also 50 drugs incorporating this molecule currently in development.
Every time one of these drugs gets approved by the FDA...
Or even passes a clinical trial...
That’s a Lightning Strike for our royalty company. That’s what I mean when I say this company is like a lightning rod. It has SO many catalysts coming in the future. You couldn’t have picked a better time to start profiting from this...
Because clinical trials and approvals can be one of the most powerful catalysts in the entire market.
For example, Aquinox Pharmaceuticals jumped nearly 1,000% in just three days on good clinical trial data.
There’s no other event in the market that can get investors this excited.
And in fact, drug royalty companies offer some of the biggest gains every time they experience a Lightning Strike.
Let me show you the incredible gains other drug royalty companies have delivered in the past.
Developing Breakthrough Treatments for Cash Windfalls Like Nothing Else in the Market
Take a look at Ionis Pharmaceuticals...
Last year it collected $112.5 million in royalties from a drug called Spinraza.
It’s a drug that’s helping people with spinal muscular atrophy stop the progression of their disease – and even increase their motor function.
Bloomberg called it “one of the best launches of a rare-disease drug in memory.”
But here’s the thing. Ionis didn’t have to grind out all the sales and marketing for this drug.
It licensed it out to Biogen, which did all the heavy lifting.
Ionis just sits back and collects the royalties.
It’s this business model that sent shares of Ionis skyrocketing.
Since 2007, it’s collected more than $2.4 BILLION in cash royalties and similar agreements.
And the stock?
It delivered a 2,652% gain since 2015!
Every $5,000 turned into $132,600.
Most investors missed out because they had no idea just how profitable drug royalties can be.
You probably also missed out on Enzon Pharmaceuticals.
It collects royalties on a drug called PegIntron.
It’s a drug for hepatitis C. And every time a prescription is filled, Enzon gets a piece of the proceeds.
For years and years, the cash comes rolling in.
It’s this business model that helped propel its stock a massive 5,260% over time!
This business model is so profitable that Carl Icahn took a 15% stake in this company a couple years ago. He bought almost 6.6 million shares.
Investors also had the opportunity to make a killing on Incyte Corporation, another biotech royalty company focusing largely on cancer and immunotherapy.
Much like the company I’m recommending today, Incyte locked down royalty agreements with pharmaceutical powerhouses like...
Because of cash-rich agreements like these, Incyte delivered a massive 7,347% gain between 2009 and 2017!
$5,000 here turned into $367,350.
Most mainstream investors have no idea these specialized drug royalty companies exist...
But they have IMMENSE potential for growth.
And remember, the company that could hand you 3,000% has 18 FDA-approved drugs in its royalty portfolio... and 165 drugs in total! It’s set to collect $184 million this year alone... and perhaps as much as $5.8 billion going forward.
When these drug royalties start paying out in full, the profits will be immense.
This stock will take off.
And if you’re not in by then, your chance at becoming a millionaire in one year will likely evaporate.
My 3,000% estimate could end up being conservative.
There are dozens of examples of biotech stocks that experience a Lightning Strike... and then blast higher by even more than 3,000%.
After all, Incyte went up more than twice that amount.
There’s also Intuitive Surgical, which went up 4,876% after getting FDA clearance for its da Vinci Surgical System...
Jazz Pharmaceuticals, which skyrocketed 5,839% after announcing stellar Phase 3 data for a fibromyalgia drug...
And Medivation, which soared a whopping 9,923% after acquiring revolutionary compounds for prostate cancer.
And remember, my 519% guarantee on AbbVie was just one-fifth the actual gain...
We made 2,381% – and we did it in less time too.
Anthony Valentino’s family ended up making $1.3 million.
But too many missed their opportunity.
Which, again, is why I’m giving away one free year of Lightning Trend Trader today.
I want to ensure not one single subscriber misses this next 3,000% opportunity.
But you must act quickly.
I’m confident this company won’t stay under the radar for long.
So to maximize your chance at 3,000%, you need to act now.
I’m expecting big new drug royalty announcements to hit on June 30.
A DEEP Portfolio of Revolutionary Treatments... All Primed for Lightning Strikes!
For example, our biotech royalty company has an agreement to collect on a drug called Sparsentan.
It’s being developed by a company called Retrophin. It’s for a serious kidney disorder that affects 40,000 Americans.
Sparsentan is currently in Phase 3 trials, which is the last stage before FDA approval.
Passing Phase 3 is, of course, another potential Lightning Strike. But that’s not where the catalysts end.
Sparsentan’s approval – which is likely, according to analysts – will make it the FIRST drug to help people suffering from this disease...
And that means a virtual monopoly when it hits the market.
That’s why analysts estimate it’s as much as an $800 million opportunity.
Our biotech royalty company will collect 9% of all sales of this drug.
That would amount to $72 million...
WITHOUT having to lift a finger!
It also has a royalty on a Pfizer drug for preventing osteoporosis, which is soon to be a $25 BILLION market.
It collects a royalty on a Novartis drug for a rare blood disorder, yielding an estimated $70 million this year...
There’s an antiviral drug in development with Gilead Sciences that treats terrifying diseases like Ebola and other viruses...
And our drug royalty company even has rights to a whole new type of drug called human therapeutic antibodies. This cutting-edge development is the industry’s fastest-growing class of drugs, set to do $115 billion in annual sales.
Dozens of Big Pharma companies are using and developing this type of drug.
And again, our drug royalty company is in the catbird seat.
It’s set to collect royalties from pharma giants like Merck, Teva, Celgene, AbbVie, Aptevo and more.
I could go on and on. The company’s drug royalties span all sorts of diseases and subsectors of the biotech market.
Its portfolio is so deep...
That the revenue potential is off the charts.
If, between the winners and losers, these 165 drugs pull in an average of just $500 million...
And this small biotech collects an average of just 7% in royalties (even though many of its rates are much higher)...
That comes out to $5.8 billion in sales...
A 3,039% increase!
But because of this company’s partnerships with the power players in biotech...
I believe the sales and royalty streams could end up much higher.
I’m extremely excited to share this with you.
Now, before I tell you how you can get your hands on this play...
And how to claim your free year of Lightning Trend Trader – valued at $4,000 – so you can grab the chance to make a million dollars in one year...
I want to answer a question that’s probably burning in your mind right now.
My Risk Management Is So Sharp,
My Service Blows the S&P 500 Out of the Water
You may have heard that biotechs are risky.
And if you don’t know what you’re doing, that certainly can be true.
If you risk it all on one clinical trial without knowing the science and the leadership behind the company...
You could be in trouble.
But if you have an expert on your side, you could make a life-changing amount of money.
Again, here’s the track record of Lightning Trend Trader vs. the S&P 500.
This isn’t cherry-picked. It includes all my winners and all my losers.
How is this possible?
I have a proprietary strategy that allows me to dominate the market’s returns. (I’ll show you each detail in your report when you claim your free year of Lightning Trend Trader.)
So even though the S&P 500 has been in a raging bull market...
My returns make it look like a flatline!
As I’ve already mentioned, this strategy is what helped subscribers collect $200,000... $1.3 million... even $2.4 million!
You don’t get this far without a strategy to manage your risk... and let your winners run for as long as possible.
In fact, managing risk is my specialty. It’s a discipline I’ve developed for a very important reason.
I have more than 600,000 readers all around the world.
They read everything I write...
And that means I have an incredible responsibility.
I never want my subscribers to lose.
So I’m ALWAYS considering risk.
With my service, I’ll give you a “buy-up-to” price so you don’t lose a cent of profit potential...
I’ll show you how to slash your downside...
And I’ll even show you a way to collect MASSIVE gains “risk-free.” This method was a big part of my 2,381% millionaire-minting win.
The key is making sure you have maximum upside and minimum downside risk...
Especially on plays with as much upside as the 3,000% winner I’ll share with you today.
This trade is built to be as low-risk as possible.
It’s not a company with one experimental treatment that could fail and tank the stock price.
Remember, this biotech royalty company has 18 FDA-approved drugs already paying out... and 165 potential royalty streams across all different stages of drug development...
And it’s always looking for more.
Think of it like a well-diversified retirement portfolio...
Except with a LOT more upside.
This is hedge fund-quality research.
Again, I’m even guaranteeing your chance at success here.
So if you’ve been watching your index funds painstakingly inch up over the years...
And you’re afraid it won’t be enough to retire on...
You need to claim your free year of Lightning Trend Trader at the end of this presentation.
Here’s what you’ll get when you do that...
An Elite Research Service You’ll Never Want to Be Without
When you join, I’ll send you all the details on the small drug royalty company I believe could make you a millionaire.
Everything you need to know is included in my special report, “How to Become a Drug Royalty Millionaire in 1 Year.”
The title may seem outlandish, but I’ve already proven it’s achievable.
You’ll see exactly what steps to take to potentially make 3,000% on this small biotech royalty company.
But I won’t just leave you with the report.
You’ll also have a free year of Lightning Trend Trader, where I’ll guide you every step of the way.
You’ve seen the massive market outperformance...
You’ve seen the winners, like my exceptional gains of 775%... 1,039%... 2,381%... and more...
And you’ve heard the stories of people who took my recommendations and rode them to millions...
But let me show you how it actually works...
And how you can use my service to accumulate riches far faster than you ever thought possible.
Lightning Trend Trader is an elite research service that costs $4,000 per year.
As soon as you subscribe, I’ll send you an email with a private password.
This password is the only way to log into the Lightning Trend Trader website. Please do not share this with anyone.
Once you log in, you’ll have access to our current model portfolio. It has quite a few open “Buy” recommendations you can act on TODAY.
Each of these recommendations is primed for a Lightning Strike in the next few months – at the latest.
And that’s not all.
Every month, I’ll send you one to three MORE recommendations. Each represents a Lightning Strike coming your way.
These recommendations will come in the form of instant profit alerts in your inbox. I’ll detail everything you need to know in a quick email.
That way you can take decisive action in the market...
And position yourself for Lightning Strike after Lightning Strike!
These little-known market events have led my subscribers to top gains of 419%... 775%... 1,039%... and 2,381%!
Lightning Strikes are a great way to build your fortune... or even catch up on retirement savings.
Reader Bruce Windsor wrote...
Colin Jones wrote...
I get notes like these from subscribers all the time across all my services...
Including this one from Kevin Hannigan. When he started following me, he had $381,000 in his investment account.
But now, he writes...
And I realize it takes more than just a hot stock tip to get there.
When you’re on my elite Lightning Trend Trader list, I don’t just send you on your way with some picks.
I’ll also alert you when it’s time to sell and take home your profits...
I’ll send you a portfolio update every single week. This way, you’re never in the dark about our positions...
I’ll send you top-of-the-line research on the markets and each recommendation so you can decide if it’s right for you.
And I’ll be here every step of the way on your journey to a million dollars.
Now, before I show you how to claim your free year of Lightning Trend Trader... and how to access my new report, “How to Become a Drug Royalty Millionaire in 1 Year”...
I have one more bonus I’d like to send you today.
ANOTHER Opportunity to Profit Nearly 3,000%
In my research, I come across all sorts of revolutionary technologies and treatments...
But very rarely do I come across true CURES.
I recently discovered a technology that could wipe 4,800 so-called “incurable” diseases from the face of the Earth.
MIT Technology Review calls it “the biggest biotech discovery of the century.”
I believe they’re underselling it.
The fact is... this technology might just be the most remarkable, lifesaving and lucrative medical breakthrough of all time.
I call it the “Genesis Cure.”
It has the power to erase genetic diseases at their source, quickly and inexpensively.
This means it could cure as many as 4,800 diseases... and take over a $1 trillion market.
One small Boston lab behind this technology could hand you 2,907% gains.
Clinical trials on this technology are set to start very soon, so you’ll want to get in as soon as possible. Today, ideally.
So when you claim your free year of Lightning Trend Trader, I’ll also rush you a copy of my breakthrough report on this opportunity.
It’s called “The Genesis Cure: How to Profit From the Biggest Medical Breakthrough in History.”
But I’ll send it to you for FREE today when you join Lightning Trend Trader.
So that’s TWO different chances to make about 3,000%...
Along with a free year of access to my market-thrashing service, where you’ll get another 12 to 36 picks set to experience Lightning Strikes over the next year.
If you’re ready to start this journey...
And FINALLY start boosting your retirement account in a fast, lower-risk way...
I’m willing to make you a special offer.
How to Claim Your FREE Year of Lightning Trend Trader
As I said before, one year of my service costs $4,000.
And today I’m giving an extra year free to anyone who signs up for my service.
So you’ll actually get two years total.
So for the price of $4,000, the one-year price, you’ll actually get a total of two years of Lightning Trend Trader.
It’s perhaps the best deal I’ve ever made for my service.
And I’m making it purely because I want to ensure NOBODY misses out on the opportunity to take advantage of this play.
Now, because of this incredible value...
And the fact that I’ll instantly send you not one but TWO reports detailing 3,000% opportunities...
Not to mention the FREE year of service...
All sales today are final.
Otherwise, thousands of people would sign up, get two of the best picks I’ve ever come across...
And then cancel.
That wouldn’t be fair to honest people like you who are serious about becoming a millionaire.
We also would not be able to stay in business that way.
However, I want to honor the fact that you’re putting your trust in me today.
So I have not one... but TWO guarantees today.
An Ironclad, Double-Fortified Guarantee
I mentioned earlier that I’m GUARANTEEING a chance for a 3,000% gain.
Here’s how it’ll work.
Now, keep in mind, I can make this guarantee only until AFTER a full year’s subscription is up.
3,000% doesn’t happen overnight, so all I ask is that you give me the full chance to deliver.
And if I don’t, just call us up, and the credit will be yours.
And it still doesn’t end there.
And as a thank-you for signing up for my service, you can keep your special reports, no hard feelings.
Sounds crazy, I know.
But that’s how much I want you in on my service today. I’m confident you’re going to love it.
My current subscribers are thrilled with my research.
Al Atkinson wrote...
And my research is so thorough and low-risk, professional investment advisors look to me for help.
Reader Larry Frank wrote me and said...
Christopher Miller, a former senior VP of investments, said...
I want you to be the next reader to benefit from my research.
This is Your Chance at a “Redo” on Becoming a Millionaire!
Too many people missed out last time. My 2,381% gain could have changed your life in just 10 months.
With my newest biotech royalty play, you have the chance to collect 3,000%.
So if you pass up on this opportunity, there’s really nothing else I can do for you.
If you’re not ready to take your retirement into your own hands today...
You’re better off clicking out right now. I don’t want to take any more of your time.
Yes, everyone says they want to get rich.
Perhaps you always dreamed of becoming a millionaire.
But very few people want to make a change in their actions to get there.
More importantly, almost no one thinks about WHY they want to be rich.
Having the right reasons in mind will make it so much easier to achieve your goal.
Do you want to travel the world without a second thought?
Do you want to buy that second home in your favorite vacation spot?
Or maybe you just want to sleep well at night, knowing all your finances are in order.
This video is your opportunity to finally achieve your goals with an expert by your side.
My report, “How to Become a Drug Royalty Millionaire in 1 Year” – and the 3,000% pick it contains – is the culmination of my 22 years in the markets...
I’ve boiled everything you need to know down to an easy three-step process...
And I’m giving it away for FREE, along with a free year of Lightning Trend Trader.
In short, I’m making this as easy as possible today...
Sign up before midnight tonight to ensure you have the chance to become a millionaire in one year.
Click the “YES! I want the chance to make $1 million” button below to get started now.
It’ll take you to a secure page where you can review everything before it’s final.
I’ve proven the power of my strategy...
And I’ve told you the stories of people who collected as much as $2.7 million by following my research.
The rest is up to you.
You can continue watching your money creep up little by little...
Pulling out your hair every time the market dips a few points...
OR you can join me and position yourself to make a million dollars...
And finally be free!
Just click the big button below and then enter your information in the secure form so we know where to send your special report, “How to Become a Drug Royalty Millionaire in 1 Year”...
And so we know where to send your free year’s worth of Lightning Trend Trader alerts and guidance.
I even have a special bonus for you when you click through to the next page.
It’s an opportunity to address one of the biggest medical crises of this century...
Click the button below now to find out more...
And claim your free year of Lightning Trend Trader!
Thanks for listening.
© 2018 The Oxford Club, LLC. The Oxford Club is a financial publisher that does not act as a personal investment advisor for any specific individual. Nor do we advocate the purchase or sale of any security or investment for any specific individual. Club Members should be aware that although our track record is highly rated by an independent analysis, and has been legally reviewed for this presentation, investment markets have inherent risks and there can be no guarantee of future profits. Likewise, our past performance does not assure the same future results. All the recommendations communicated to members during the life of this service may not be reflected in this presentation. The stated returns may also include option trades. We will send all our members regular communications with specific, timely strategies and updated recommendations; however, you should not consider any of the communications by our company and employees to you personalized investment advice. Note that the proprietary recommendations and analysis we present to members is for the exclusive use of our membership.